Ingestion of probiotics (a Lactobacillus rhamnosus formula) as complementary therapy in the treatment of patients with plaque psoriasis (an inflammatory disease of the skin)
Not Applicable
Completed
- Conditions
- PsoriasisC17.800
- Registration Number
- RBR-8js7t83
- Lead Sponsor
- Enrico Stefano Suriano
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Data analysis completed
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Being over 18 years old; having plaque psoriasis.
Exclusion Criteria
Being pregnant; having other skin diseases, neoplasms or systemic inflammatory diseases (such as Crohn’s disease, inflammatory bowel disease, vasculitis and sarcoidosis).
Study & Design
- Study Type
- Intervention
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in mean PASI (Psoriasis Area of Severity Index). In the beginning of the study, we expected to find a difference of 30% between groups after 6 months of administration of probiotics. After the study was completed, the observed difference was of 20% (reduction of mean PASI of 3.06 in the experimental group and of 2.46 in the control group, with p=0.62).
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the efficacy of Lactobacillus rhamnosus in plaque psoriasis immunopathology?
How does probiotic therapy with Lactobacillus rhamnosus compare to standard-of-care treatments like biologics in psoriasis outcomes?
Which biomarkers are associated with response to Lactobacillus rhamnosus in patients with C17.800 psoriasis subtypes?
What are the potential adverse events and safety management strategies for Lactobacillus rhamnosus in psoriasis treatment?
Are there synergistic combination approaches involving Lactobacillus rhamnosus and conventional psoriasis therapies like methotrexate or apremilast?